Haemonetics
Open
$77.59
Prev. Close
$77.66
High
$78.20
Low
$77.41
Market Snapshot
$3.63B
37.3
2.56
$1.37B
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). The company also offers solutions for structural heart and endovascular procedures.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). The company also offers solutions for structural heart and endovascular procedures.
Recently from Cashu
Haemonetics Restructures Segments to Enhance Clarity and Operational Efficiency in Healthcare Solutions
Haemonetics Corporation (Ticker: HAE), a global medical technology company focused on enhancing patient outcomes through innovative solutions, announces a significant restructuring of its reportable s…
Haemonetics Showcases Innovations at Goldman Sachs Global Healthcare Conference 2026
Haemonetics (Ticker: HAE) is poised to showcase its strategies and innovations at the Goldman Sachs 47th Annual Global Healthcare Conference, a significant platform for dialogue with investors. Presid…
Haemonetics Unveils Superior Vascular Closure System with FDA Approval and Clinical Study Results
Haemonetics Corporation has recently released compelling clinical study results for its VASCADE MVP XL vascular closure system, indicating that it delivers superior performance compared to the origina…
Haemonetics Innovates with VASCADE MVP XL, Enhancing Outcomes in Vascular Closure Technology
Haemonetics Corporation showcases innovation in medical technology with the recent release of clinical study results for its VASCADE MVP XL vascular closure system, which significantly outperforms its…